American Journal of Cardiology
Volume 104, Issue 6 , Pages 745-749 , 15 September 2009

Impact of Homocysteine-Lowering Vitamin Therapy on Long-Term Outcome of Patients With Coronary Artery Disease

  • Aviv Mager, MD

      Affiliations

    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel
    • Corresponding Author InformationCorresponding author: Tel: 972-3-9377107; fax: 972-3-9249850
  • ,
  • Katia Orvin, MD

      Affiliations

    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel
  • ,
  • Nira Koren-Morag, PhD

      Affiliations

    • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • ,
  • Israel Eli Lev, MD

      Affiliations

    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel
  • ,
  • Abid Assali, MD

      Affiliations

    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel
  • ,
  • Ran Kornowski, MD

      Affiliations

    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel
  • ,
  • Mordechai Shohat, MD

      Affiliations

    • Medical Genetic Institute, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel
  • ,
  • Alexander Battler, MD

      Affiliations

    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel
  • ,
  • David Hasdai, MD

      Affiliations

    • Department of Cardiology, Rabin Medical Center, Beilinson Campus, FMRC, Petah Tikva, Israel

Received 21 February 2009 ,Revised 2 May 2009 ,Accepted 2 May 2009.

References 

  1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol. 1969;56:111–128
  2. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
  3. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–2022
  4. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286–291
  5. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollest SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236
  6. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042–1050
  7. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG MTHFR Studies Collaboration Group. MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002;288:2023–2031
  8. Mager A, Lalezari S, Shohat T, Birnbaum Y, Adler Y, Magal N, et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation. 1999;100:2406–2410
  9. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rosen R, et al. Homocysteine and the risk of premature coronary heart disease. Circulation. 1996;94:2154–2158
  10. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor coronary artery disease. Circulation. 1997;95:2032–2036
  11. Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997;96:2573–2577
  12. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410–2416
  13. van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21–23
  14. Wilken DE, Wilken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997;20:295–300
  15. Kluijtmans LA, Boers GH, Kraus JP, van den Heuvel LP, Cruysberg JR, Trijbels FJ, et al. The molecular basis of cystathionine beta-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet. 1999;65:59–67
  16. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA. 1998;279:359–364
  17. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol. 2003;41:2105–2113
  18. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  19. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
  20. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA. 2008;299:2027–2036
  21. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795–804
  22. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298:1163–1170
  23. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379–386
  24. Potena L, Grigioni F, Masetti M, Magnani G, Coccolo F, Fallani F, et al. Long-term effect of folic acid therapy in heart transplant recipients: follow-up analysis of a randomized study. Transplantation. 2008;85:1146–1150
  25. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 2001;345:1593–1600
  26. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA. 2002;288:973–979
  27. Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673–2681
  28. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  29. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase gene. Nat Genet. 1995;10:111–113
  30. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9–19

 This study was supported in part by an institutional research grant from Rabin Medical Center, Petah Tikva, Israel.

PII: S0002-9149(09)01046-7

doi: 10.1016/j.amjcard.2009.05.011

American Journal of Cardiology
Volume 104, Issue 6 , Pages 745-749 , 15 September 2009